Antenatal Dexamethasone: Effect on Ovine Placental 11β-Hydroxysteroid Dehydrogenase Type 2 Expression and Fetal Growth

Leslie S Kerzner,Barbara S Stonestreet,Ke-Ying Wu,Grazyna Sadowska,Maureen P Malee
DOI: https://doi.org/10.1203/00006450-200211000-00016
IF: 3.953
2002-01-01
Pediatric Research
Abstract:Antenatal glucocorticoids are routinely given to women at risk for preterm delivery. The fetus is protected from excessive glucocorticoids by the placental enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD-2), which catalyzes the conversion of cortisol to its biologically inactive metabolite, cortisone. We examined the effects of antenatal dexamethasone on the expression of placental 11β-HSD-2 in fetal sheep. Ewes were randomized to receive repeated or single courses of dexamethasone or placebo beginning at 76-78 or 104-106 d of gestation, respectively. In the single course group, the ewes received dexamethasone (6 mg, n = 7) or placebo ( n = 6) as four intramuscular injections over 48 h up to 18 h before placental harvest. In the repeated course group, the ewes received the same treatment (dexamethasone, n = 10, or placebo, n = 9) once a week for 5 consecutive weeks starting at 76–78 d of gestation. Placental harvest occurred at 106–108 d of gestation in the four groups. By semi-quantitative RT-PCR, we found that placental 11β-HSD-2 expression was lower in the fetuses of ewes exposed to a single course of dexamethasone than placebo ( p < 0.05). Placental 11β-HSD-2 expression did not differ significantly between fetuses of ewes treated with repeated courses of dexamethasone compared with placebo, or a single course of dexamethasone. Fetuses of dexamethasone treated ewes weighed less than those of placebo treated ewes (ANOVA, main effects for dexamethasone versus placebo treatment: F = 14.5, p = 0.007). Fetuses of ewes exposed to repeated courses of dexamethasone weighed less than those of ewes exposed to placebo or a single course of dexamethasone ( p < 0.05). We conclude that maternal antenatal dexamethasone treatment reduces placental 11β-HSD-2 expression and fetal weight at mid-gestation in the ovine pregnancy.
What problem does this paper attempt to address?